Source: Fullscript Blog

Fullscript Blog Seamlessly introducing supplements to elevate patient care

This presentation will review clinical assessments for evaluating the integrity of the intestinal barriers and testing to determine the presence of systemic bacterial toxins and predictive antibodies for cardiovascular disease. Detailed clinical approaches and treatment protocols for restoring damaged barriers and eliminating gut dysbiosis will also be discussed.

Read full article »
Est. Annual Revenue
$100-500M
Est. Employees
500-1.0K
Kyle Braatz's photo - Co-Founder & CEO of Fullscript

Co-Founder & CEO

Kyle Braatz

CEO Approval Rating

99/100

Read more